Absence of

Joseph A. Jakubowski; Ying G. Li; Christopher D. Payne; David S. Small; Kenneth J. Winters

doi:10.1160/TH10-11-0764

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 106(01): 174-176
DOI: 10.1160/TH10-11-0764

Letters to the Editor

Schattauer GmbH

Absence of "rebound" platelet hyperreactivity following cessation of prasugrel

Joseph A. Jakubowski

¹Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA

,

Ying G. Li

¹Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA

,

Christopher D. Payne

²Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK

,

David S. Small

¹Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA

,

Kenneth J. Winters

¹Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA

› Author Affiliations

Abstract

Full Text

References

References
1 Ho PM, Peterson ED, Wang L. et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. J Am Med Assoc 2008; 299: 532-539.
2 Ho PM, Tsai TT, Wang TY. et al. Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system. Circ Cardiovasc Qual Outcomes 2010; 3: 303-308.
3 Jakubowski JA, Stampfer MJ, Vaillancourt R, Dey- kin D.. Cumulative antiplatelet effect of low-dose enteric coated aspirin. Br J Haematol 1985; 60: 635-642.
4 Jakubowski JA, Payne CD, Brandt JT, Weerakkody GJ, Farid NA, Small DS. et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol 2006; 47: 377-384.
5 Jakubowski JA, Payne CD, Weerakkody GJ, Brandt JT, Farid NA, Li YG. et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol 2007; 49: 167-173.
6 Jakubowski JA, Payne CD, Li YG. et al. A comparison of the antiplatelet effects of prasugrel and highdose clopidogrel as assessed by VASP-phosphory- lation and light transmission aggregometry. Thromb Haemost 2008; 99: 215-222.
7 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006; 55: 780-784.
8 Sibbing D, Stegherr J, Braun S. et al. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol 2010; 55: 558-565.
9 Mylotte D, Peace AJ, Tedesco AT. et al. Clopidogrel discontinuation and platelet reactivity following coronary stenting. J Thromb Haemost 2011; 9: 24-32.
10 Frelinger AL III, Barnard MR, Fox ML. et al. The Platelet Activity After Clopidogrel Termination (PACT) study. Circ Cardiovasc Interv 2010; 3: 442-449.
11 Lordkipanidze M, Diodati JG, Pharand C. Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence. Pharmacol Ther 2009; 123: 178-186.
12 Sambu N, Warner T, Curzen N. Clopidogrel withdrawal: Is there a “rebound” phenomenon?. Thromb Haemost 2011; 105: 211-220.
13 Gurbel PA, Bliden KP, Butler K. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585.

Supplementary Material

Online Supplementary Material (PDF)